Monopar Therapeutics Inc. (NASDAQ:MNPR) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) by 174.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,596 shares of the company's stock after buying an additional 24,530 shares during the quarter. Geode Capital Management LLC owned 0.63% of Monopar Therapeutics worth $849,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth about $45,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR traded down $0.38 during trading on Wednesday, hitting $38.40. 12,120 shares of the company were exchanged, compared to its average volume of 359,079. The firm's 50 day moving average price is $36.41 and its 200-day moving average price is $30.48. Monopar Therapeutics Inc. has a 12-month low of $1.72 and a 12-month high of $54.30. The stock has a market capitalization of $234.79 million, a P/E ratio of -19.49 and a beta of 1.11.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, equities research analysts anticipate that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MNPR. Piper Sandler reaffirmed an "overweight" rating and issued a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Finally, Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd.

Insiders Place Their Bets

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the transaction, the insider now owns 822,255 shares of the company's stock, valued at approximately $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 34.90% of the stock is currently owned by insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.